Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks

This article was originally published in The Pink Sheet Daily

Executive Summary

Novel adaptive randomized discontinuation design tested cabozantinib in nine tumor types, isolated best opportunities faster than traditional randomization.

You may also be interested in...



Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer

As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.

Exelixis Explains Virtues Of Flat Pricing For Cometriq

Approval in very rare medullary thyroid cancer marks an important milestone for Exelixis’ Cometriq (cabozantinib), which is being positioned for multiple cancers. The company will need only five sales reps for the thyroid cancer market and plans to launch in late January 2013 at the price of $9,900 per 28 days.

Simulation Of Clinical Scenarios Important To Support Adaptive Trial Designs

FDA has approved one drug supported by an adaptive design, but the trial did not save money or time, FDA statistician tells regulatory professionals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel